# Peginterferon beta-1a

## Plegridy inj 63mcg

##### 臨採

| TAH Drug Code      | [IPLE1](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IPLE1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|:-------------------|:-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Plegridy is indicated in adult patients for the treatment of relapsing remitting multiple sclerosis.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Dosing             | The recommended dose of Plegridy is 125 micrograms injected SC every 2 weeks (14 days). Treatment initiation: It is generally recommended that patients start SC treatment with 63 micrograms at dose 1 (on day 0), increasing to 94 micrograms at dose 2 (on day 14), reaching the full dose of 125 micrograms by dose 3 (on day 28) and continuing with the full dose (125 micrograms) every 2 weeks (14 days) thereafter.                                                                                                                                                                                                                                                                                                                                                                                 |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Contraindications  | Hypersensitivity to natural or recombinant interferon beta or peginterferon or to any of the excipients. Patients with current severe depression and/or suicidal ideation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Adverse Effects    | Common Dermatologic: Erythema at injection site (subQ, 25% to 62% ), Injection site pain (11% to 15% ), Injection site pruritus (13% ) Musculoskeletal: Arthralgia (11% ) Neurologic: Asthenia (13% ), Headache (36% to 44% ) Other: Fever (45% ), Influenza-like illness (47% ), Shivering (17% to 36% ) Serious Cardiovascular: Congestive heart failure Dermatologic: Injection site necrosis Hematologic: Decreased lymphocyte count (Less than 1% ), Decreased platelet count (Less than 1% ), Decreased white blood cell count (7% ), Neutropenia (Less than 1% ), Pancytopenia (Rare ), Thrombocytopenia Hepatic: Autoimmune hepatitis, Hepatitis, Liver failure Immunologic: Autoimmune disease (Less than 1% ) Neurologic: Seizure (Less than 1% ) Psychiatric: Suicidal thoughts Other: Angioedema |
| Pregnancy          | No (Limited) Human Data – Animal Data Suggest Moderate Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Lactation          | No (Limited) Human Data - Probably Compatible                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| More Info          | [UpToDate](https://www.uptodate.com/contents/peginterferon-beta-1a-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |

## Plegridy inj 94mcg

##### 臨採

| TAH Drug Code      | [IPLE2](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IPLE2)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|:-------------------|:-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Plegridy is indicated in adult patients for the treatment of relapsing remitting multiple sclerosis.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Dosing             | The recommended dose of Plegridy is 125 micrograms injected SC every 2 weeks (14 days). Treatment initiation: It is generally recommended that patients start SC treatment with 63 micrograms at dose 1 (on day 0), increasing to 94 micrograms at dose 2 (on day 14), reaching the full dose of 125 micrograms by dose 3 (on day 28) and continuing with the full dose (125 micrograms) every 2 weeks (14 days) thereafter.                                                                                                                                                                                                                                                                                                                                                                                 |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Contraindications  | Hypersensitivity to natural or recombinant interferon beta or peginterferon or to any of the excipients. Patients with current severe depression and/or suicidal ideation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Adverse Effects    | Common Dermatologic: Erythema at injection site (subQ, 25% to 62% ), Injection site pain (11% to 15% ), Injection site pruritus (13% ) Musculoskeletal: Arthralgia (11% ) Neurologic: Asthenia (13% ), Headache (36% to 44% ) Other: Fever (45% ), Influenza-like illness (47% ), Shivering (17% to 36% ) Serious Cardiovascular: Congestive heart failure Dermatologic: Injection site necrosis Hematologic: Decreased lymphocyte count (Less than 1% ), Decreased platelet count (Less than 1% ), Decreased white blood cell count (7% ), Neutropenia (Less than 1% ), Pancytopenia (Rare ), Thrombocytopenia Hepatic: Autoimmune hepatitis, Hepatitis, Liver failure Immunologic: Autoimmune disease (Less than 1% ) Neurologic: Seizure (Less than 1% ) Psychiatric: Suicidal thoughts Other: Angioedema |
| Pregnancy          | No (Limited) Human Data – Animal Data Suggest Moderate Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Lactation          | No (Limited) Human Data - Probably Compatible                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| More Info          | [UpToDate](https://www.uptodate.com/contents/peginterferon-beta-1a-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |

## PLEGRIDY inj 125mcg

##### 臨採

| TAH Drug Code      | [IPLE3](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IPLE3)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|:-------------------|:-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Plegridy is indicated in adult patients for the treatment of relapsing remitting multiple sclerosis.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Dosing             | The recommended dose of Plegridy is 125 micrograms injected SC every 2 weeks (14 days). Treatment initiation: It is generally recommended that patients start SC treatment with 63 micrograms at dose 1 (on day 0), increasing to 94 micrograms at dose 2 (on day 14), reaching the full dose of 125 micrograms by dose 3 (on day 28) and continuing with the full dose (125 micrograms) every 2 weeks (14 days) thereafter.                                                                                                                                                                                                                                                                                                                                                                                 |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Contraindications  | Hypersensitivity to natural or recombinant interferon beta or peginterferon or to any of the excipients. Patients with current severe depression and/or suicidal ideation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Adverse Effects    | Common Dermatologic: Erythema at injection site (subQ, 25% to 62% ), Injection site pain (11% to 15% ), Injection site pruritus (13% ) Musculoskeletal: Arthralgia (11% ) Neurologic: Asthenia (13% ), Headache (36% to 44% ) Other: Fever (45% ), Influenza-like illness (47% ), Shivering (17% to 36% ) Serious Cardiovascular: Congestive heart failure Dermatologic: Injection site necrosis Hematologic: Decreased lymphocyte count (Less than 1% ), Decreased platelet count (Less than 1% ), Decreased white blood cell count (7% ), Neutropenia (Less than 1% ), Pancytopenia (Rare ), Thrombocytopenia Hepatic: Autoimmune hepatitis, Hepatitis, Liver failure Immunologic: Autoimmune disease (Less than 1% ) Neurologic: Seizure (Less than 1% ) Psychiatric: Suicidal thoughts Other: Angioedema |
| Pregnancy          | No (Limited) Human Data – Animal Data Suggest Moderate Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Lactation          | No (Limited) Human Data - Probably Compatible                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| More Info          | [UpToDate](https://www.uptodate.com/contents/peginterferon-beta-1a-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |

